Potentiated CD16 activated ADCC CAR-NK cells

In humans, there are two types of FcγR: the activating receptor, which contains the CD64 (FcγRI), CD32a (FcγRIIA), CD32c (FcγRIIC), CD16a (FcγRIIIA), and CD16b (FcγRIIIB); and the inhibiting receptor, CD32b (FcγRIIB). Table 1 lists the types and characteristics of FcγRs.

Table 1. The types and characteristics of FcγRs. Source: Sino Biological Inc.

Name	FcγRI/CD64	FcγRIIA/CD32a	FcγRIIB/CD32b	FcγRIIC/CD32c	FcγRIIIA/CD16a	FcγRIIIB/CD16b
Structure
Function	Activating	Activating	Inhibitory	Activating	Activating	Activating
Affinity	High	Low	Low	Low	Low	Low
Effect of Antibody Binding	ADCP, cytokine release	ADCC, ADCP, vaccinal effect	Inhibits ADCC, ADCP, B cell activation	Enhances ADCC, ADCP, B cell activation	ADCC, ADCP	Decoy receptor that inhibits ADCP

To mediate antibody-dependent cellular cytotoxicity (ADCC), NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA). A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells.

CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other activating receptors (e.g., NKG2D, DNAM-1/CD226, NKp46/NCR1, NKp44/NCR2, and NKp30/NCR3), scFvs for tumor antigens (e.g., CD19, CD22, ROBO1, and PSMA), and cytokine moieties (e.g. CD16 genetic modifications to eliminate sensitivity to ADAM-17-mediated proteolytic cleavage or increase affinity for IgG Fc region have shown promising results.

Learn More About The Reagents

CAR-NK cells expressing CD16A in recombination with the high-affinity Fc receptor, CD64 (FcγRI), demonstrate a more stable and enhanced ADCC response, indicating a promising advancement in CAR-NK cell immunotherapy.

Figure 1. Mechanism of CAR-NK cell-mediated ADCC. Image Credit: Sino Biological Inc.

Figure 1 depicts the concept of using CAR-NK cells in combination with antibody immunotherapy to counteract NK cell impairment, in which CAR-NK cells can kill target cancer cells independently via CAR and also serve as CD16-positive effector cells for mitigating ADCC against cancer cells.

Sino Biological has created a collection of high-quality proteins and antibodies for CD16 and related molecules to aid in CAR-NK cell therapy research.

Featured recombinant CD16 and CD64 proteins

Sino Biological provides cancer immunotherapy research with CD16a, CD16b, CD64, and related protein reagents.

Image Credit: Sino Biological Inc.

Human CD16a protein. Cat#: 10389-H08H1

High-Purity: >95% as determined by SEC-HPLC. Image Credit: Sino Biological Inc.

Immobilized Human CD16a (V176) can bind human IgG1 (Cat#: 10702-HNAC). Image Credit: Sino Biological Inc.

Human CD16b protein. Cat#: 11046-H08H1

High-Purity: >90 % as determined by SEC-HPLC. Image Credit: Sino Biological Inc.

BLI assay: Load IgG1 can bind human CD16b (NA1) recombinant protein. Image Credit: Sino Biological Inc.

Human CD64 protein. Cat#: 10256-H08H

High-Purity: >90 % as determined by SEC-HPLC. Image Credit: Sino Biological Inc.

Immobilized Anti-CD20 (Ro) antibody (Cat#: 68055-H005) can bind human CD64 protein. Image Credit: Sino Biological Inc.

More recombinant FcγR proteins (partial)

Table 2. Source: Sino Biological Inc.

Other related proteins

• CD95
• TROP-2
• TRAIL
• CD19
• CTLA-4
• NKG2C
• IFN gamma
• NKG2A
• NKp80/KLRF1
• KLRB1F
• TIM3
• PD1

Featured CD16 and CD64 antibodies

Sino Biological has created a collection of antibodies for CD16a, CD16b, CD64, and related molecules for use in FCM, ELISA, IHC-P, IP, and WB.

Anti-CD16a antibody (FITC). Mouse monoclonal. Cat#: 10389-MM41-F

Flow cytometric analysis of Human CD16 expression on human whole blood lymphocyte. Image Credit: Sino Biological Inc.

Anti-CD16b antibody. Mouse monoclonal. Cat#: 11046-MM07.

Immunochemical staining of human CD16b in human spleen. Image Credit: Sino Biological Inc.

Anti-CD64 antibody. Rabbit monoclonal. Cat#: 50086-R001.

Immunochemical staining of mouse CD64 in mouse liver. Image Credit: Sino Biological Inc.

More FcγR antibodies (partial)

Table 3. Source: Sino Biological Inc.